A randomized, double-blind, placebo-controlled phase 2 study of tigatuzumab (CS-1008) in combination with carboplatin/paclitaxel in patients with chemotherapy-naïve metastatic/unresectable non-small cell lung cancer.
暂无分享,去创建一个
M. Krzakowski | J. von Pawel | R. Beckman | M. Reck | M. Sebastian | E. Chmielowska | D. Hadler | J. Greenberg | Qiang Wang | Tara Fox